On the other hand, a retrospective study evaluating ICI ± chemotherapy combinations in HER2-positive NSCLC patients observed a 52% ORR in the ICI + platinum-doublet group, with a 1-year median PFS of 6 months—higher than prior reports. Here, ERBB2 is linked to non-small cell lung carcinoma.